与编辑委员会会面-对Min孟的采访以及从小型区域实验室到全球CRO的过渡。

IF 1.9 4区医学 Q3 BIOCHEMICAL RESEARCH METHODS

Bioanalysis Pub Date : 2024-01-01 Epub Date: 2023-11-15 DOI:10.4155/bio-2023-0216

Min Meng

{"title":"与编辑委员会会面-对Min孟的采访以及从小型区域实验室到全球CRO的过渡。","authors":"Min Meng","doi":"10.4155/bio-2023-0216","DOIUrl":null,"url":null,"abstract":"Min Meng received her PhD in biomedicinal chemistry from the School of Pharmacy, University of Maryland, in 1996. From 1996 to 1998, Meng was a postdoctoral fellow at the American Health Foundation, focusing on the carcinogenic toxicity of tobacco smoke using various chromatographic technologies such as LC-UV, GC-MS/MS and LC-MS/MS. From 1998 to 2017, Meng worked for Tandem Labs/LabCorp/Covance, a bioanalytical contract research organization (CRO), holding various positions from scientist to lab director and technical director. In 2017, Meng moved back to her hometown and set up a bioanalytical CRO, Denali Medpharma, Chongqing, China. In October 2023, Denali was acquired by Resolian Bioanalytics, a global bioanalytical CRO. Currently, Dr Meng is the chief scientific officer and president of the Asia Pacific region for Resolian Bioanalytics.","PeriodicalId":8797,"journal":{"name":"Bioanalysis","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Meet the Editorial Board - an interview with Min Meng and transitions from small regional labs to global CRO.\",\"authors\":\"Min Meng\",\"doi\":\"10.4155/bio-2023-0216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Min Meng received her PhD in biomedicinal chemistry from the School of Pharmacy, University of Maryland, in 1996. From 1996 to 1998, Meng was a postdoctoral fellow at the American Health Foundation, focusing on the carcinogenic toxicity of tobacco smoke using various chromatographic technologies such as LC-UV, GC-MS/MS and LC-MS/MS. From 1998 to 2017, Meng worked for Tandem Labs/LabCorp/Covance, a bioanalytical contract research organization (CRO), holding various positions from scientist to lab director and technical director. In 2017, Meng moved back to her hometown and set up a bioanalytical CRO, Denali Medpharma, Chongqing, China. In October 2023, Denali was acquired by Resolian Bioanalytics, a global bioanalytical CRO. Currently, Dr Meng is the chief scientific officer and president of the Asia Pacific region for Resolian Bioanalytics.\",\"PeriodicalId\":8797,\"journal\":{\"name\":\"Bioanalysis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioanalysis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4155/bio-2023-0216\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioanalysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4155/bio-2023-0216","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

摘要

她于1996年获得马里兰大学药学院生物药物化学博士学位。1996年至1998年，在美国卫生基金会担任博士后研究员，主要研究烟草烟雾的致癌毒性，使用LC-UV, GC-MS/MS和LC-MS/MS等多种色谱技术。从1998年到2017年，孟在生物分析合同研究组织(CRO) Tandem Labs/LabCorp/Covance工作，担任过从科学家到实验室主任和技术总监的各种职位。2017年，孟回到家乡，在中国重庆成立了生物分析CRO——德纳里医药(Denali Medpharma)。2023年10月，Denali被全球生物分析CRO公司Resolian Bioanalytics收购。目前，孟博士是Resolian Bioanalytics亚太区首席科学官兼总裁。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Meet the Editorial Board - an interview with Min Meng and transitions from small regional labs to global CRO.

Min Meng received her PhD in biomedicinal chemistry from the School of Pharmacy, University of Maryland, in 1996. From 1996 to 1998, Meng was a postdoctoral fellow at the American Health Foundation, focusing on the carcinogenic toxicity of tobacco smoke using various chromatographic technologies such as LC-UV, GC-MS/MS and LC-MS/MS. From 1998 to 2017, Meng worked for Tandem Labs/LabCorp/Covance, a bioanalytical contract research organization (CRO), holding various positions from scientist to lab director and technical director. In 2017, Meng moved back to her hometown and set up a bioanalytical CRO, Denali Medpharma, Chongqing, China. In October 2023, Denali was acquired by Resolian Bioanalytics, a global bioanalytical CRO. Currently, Dr Meng is the chief scientific officer and president of the Asia Pacific region for Resolian Bioanalytics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Bioanalysis BIOCHEMICAL RESEARCH METHODS-CHEMISTRY, ANALYTICAL

CiteScore

3.30

自引率

16.70%

发文量

审稿时长

2 months

期刊介绍： Reliable data obtained from selective, sensitive and reproducible analysis of xenobiotics and biotics in biological samples is a fundamental and crucial part of every successful drug development program. The same principles can also apply to many other areas of research such as forensic science, toxicology and sports doping testing. The bioanalytical field incorporates sophisticated techniques linking sample preparation and advanced separations with MS and NMR detection systems, automation and robotics. Standards set by regulatory bodies regarding method development and validation increasingly define the boundaries between speed and quality. Bioanalysis is a progressive discipline for which the future holds many exciting opportunities to further reduce sample volumes, analysis cost and environmental impact, as well as to improve sensitivity, specificity, accuracy, efficiency, assay throughput, data quality, data handling and processing. The journal Bioanalysis focuses on the techniques and methods used for the detection or quantitative study of analytes in human or animal biological samples. Bioanalysis encourages the submission of articles describing forward-looking applications, including biosensors, microfluidics, miniaturized analytical devices, and new hyphenated and multi-dimensional techniques. Bioanalysis delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for the modern bioanalyst.